Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, 200240, China.
Department of Joint Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Stem Cell Res Ther. 2021 Jan 7;12(1):25. doi: 10.1186/s13287-020-02055-1.
Umbilical cord mesenchymal stem cells (UC-MSCs) have certain advantages over other MSCs and about 300 clinical trials have been registered using UC-MSCs to treat diseases such as osteoarthritis, autoimmune diseases, and degenerative disorders, yet, only limited success has been achieved. One reason is that in vitro expanded UC-MSCs show tremendous heterogeneity and their relationship to in vivo UC-MSCs remains unknown. Here, we investigated freshly isolated, uncultured UC-MSCs by single-cell RNA sequencing (scRNA-seq) and found two populations of UC-MSCs. Although UC-MSCs share many expressed genes and may have the same origin, they can be clearly separated based on differentially expressed genes including CD73 and other markers. Moreover, group 1 MSCs are enriched in expression of genes in immune response/regulatory activities, muscle cell proliferation and differentiation, stemness, and oxidative stress while group 2 MSCs are enriched with gene expression in extracellular matrix production, osteoblast and chondrocytes differentiation, and bone and cartilage growth. These findings suggest that UC-MSCs should be separated right after isolation and individually expanded in vitro to treat different diseases.
脐带间充质干细胞 (UC-MSCs) 相对于其他 MSCs 具有一定优势,目前已有约 300 项临床试验使用 UC-MSCs 来治疗骨关节炎、自身免疫性疾病和退行性疾病等疾病,但仅取得了有限的成功。原因之一是体外扩增的 UC-MSCs 表现出巨大的异质性,其与体内 UC-MSCs 的关系尚不清楚。在这里,我们通过单细胞 RNA 测序 (scRNA-seq) 研究了新鲜分离的未培养的 UC-MSCs,发现了两种 UC-MSCs 群体。尽管 UC-MSCs 具有许多共同表达的基因,可能具有相同的起源,但它们可以基于差异表达基因(包括 CD73 和其他标志物)清楚地分开。此外,第 1 组 MSC 富含免疫反应/调节活性、肌肉细胞增殖和分化、干性和氧化应激相关基因的表达,而第 2 组 MSC 富含细胞外基质产生、成骨细胞和软骨细胞分化以及骨骼和软骨生长相关基因的表达。这些发现表明,UC-MSCs 应该在分离后立即分离,并在体外分别进行扩增,以治疗不同的疾病。